Evidence map›Paper›PMID 36368335›Full record

ArticleLancet (London, England)2022

A revolution in the management of multidrug-resistant tuberculosis.

Keertan Dheda, Christoph Lange

Erratum issuedAbstract readComment
PubMed Publisher
In one paragraph

Article in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Construction and characterization of novelInfection and immunity · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Keertan DhedaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, and UCT Lung Institute and South African MRC-UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town 7935, South Africa; Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK. Electronic address: keertan.dheda@uct.ac.za.
Christoph LangeClinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Clinical Tuberculosis Unit, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany; Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Tuberculosis, Multidrug-ResistantAntitubercular AgentsHumansAntitubercular Agents

Identifiers

PMID36368335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.